GSD
vs
S
S&P TSX Composite Index (Canada)
GSD
Over the past 12 months, GSD has underperformed S&P TSX Composite Index (Canada), delivering a return of +11% compared to the S&P TSX Composite Index (Canada)'s +41% growth.
Stocks Performance
GSD vs S&P TSX Composite Index (Canada)
Performance Gap
GSD vs S&P TSX Composite Index (Canada)
Performance By Year
GSD vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Devonian Health Group Inc
Glance View
Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Pointe-Claire, Quebec. The company went IPO on 2014-09-09. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies, as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a Phase II clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis. The firm is also involved in the development of cosmeceutical products.
